Home / Rare & Genetic Diseases / April 2013

OPKO completes Latin American acquisition

The purchase allows OPKO to expand its Latin American presence, in addition to complementing its business units in Chile and Mexico, and will enable commercialization of the OPKO 4Kscore prostate cancer test in Brazil as a reference laboratory test

| 1 min read

Jeffrey Bouley

Listen with Speechify

0:00

1:00

MIAMI—OPKO Health Inc. has completed its acquisition ofSilcon Comércio, Importacao E Exportacao de Produtos Farmaceuticos e CosmeticosLtda. OPKO announced the acquisition of the San Paulo, Brazil-based company inDecember 2012, though no financial details related to the transaction weredisclosed. The purchase allows OPKO to expand its Latin American presence, inaddition to complementing its business units in Chile and Mexico, and willenable commercialization of the OPKO 4Kscore prostate cancer test in Brazil asa reference laboratory test.

"We are excited to establish our initial footprint in themost important growth market in South America and initiate commercial effortstowards the introduction of our 4Kscore test in the Brazilian market," Dr.Phillip Frost, chairman and CEO of OPKO, said in a press release.

About the Author

Jeffrey Bouley
Jeffrey Bouley

Published In

Volume 9 - Issue 4 | April 2013

April 2013

Loading Next Article...

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Tackling mycoplasma contamination in biotherapeutic production

DNA-based testing is emerging as a sensitive way to uncover and control a hidden threat in biomanufacturing.

Webinars

Surface rendering of two interacting proteins (green and peach) bound together by a small molecule ligand at their interface, illustrating a protein-ligand binding event.

Computational approaches to drug design

Learn how molecular dynamics, AI-aided design, and structural insights combine to reshape how therapeutic proteins are created, validated, and optimized.

Compendium